Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3154207
Mevidalen · 3 trials · 3 indications
iADRS assesses the impact of cognitive loss on everyday activities and provides a measure of global AD severity as a single summary score. It comprises of 2 underlying domains "cognitive ability" and "functional ability," and integrates the items in both the domains a single overall score ranging from 0 to 144, with lower scores indicating worse performance.
The CDR-CCB tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning which includes tests of attention (simple and choice reaction time, digit vigilance), working memory (spatial and numeric) and episodic memory (word recognition, picture recognition). Continuity of attention measures speed and accuracy and is calculated from 3 attentional tasks on the CDR computerized battery tests. For continuity of attention, the score range is -999 to 35. A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline. Data presented are model-based bayesian posterior mean response rates with 95% credible interval.
| Arm | Type | Description |
|---|---|---|
| Mevidalen (high dose) | EXPERIMENTAL | Mevidalen high dose administered orally. |
| Mevidalen (low dose) | EXPERIMENTAL | Mevidalen low dose administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| 10 milligram (mg) LY3154207 | EXPERIMENTAL | Participants received 10 mg LY3154207 administered orally QD. |
| 30 mg LY3154207 | EXPERIMENTAL | Participants received 30 mg LY3154207 administered orally QD. |
| 75 mg LY3154207 | EXPERIMENTAL | Participants received 75 mg LY3154207 administered orally QD. |
| LY3154207 | EXPERIMENTAL | LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days. |
| Name | Type | Description |
|---|---|---|
| Mevidalen | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| LY3154207 | DRUG | Administered orally. |
Inclusion Criteria: * Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living. * Have MMSE score of 13 to 24. * Have eligibile plasma P-tau or historical evidence of AD pathology. * Have a relia...
Top 20 of 30 competitors
Mevidalen is an investigational small molecule being studied for the treatment of Alzheimer disease. It is not approved for any indication and remains in clinical development. Eli Lilly and Company is evaluating it in a Phase 2 program, with the completed study enrolling 304 participants with Alzheimer disease.
Mevidalen targets DRD1, the dopamine D1 receptor, and acts as a positive allosteric modulator. This target class means the drug enhances receptor signaling rather than activating the receptor directly. The DRD1 mechanism is being explored in Alzheimer disease, a neurology indication, by Eli Lilly and Company.
Mevidalen is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The compound is also referenced in discovery records as LY3154207. Lilly is the sponsor of the clinical program evaluating Mevidalen in Alzheimer disease.
Mevidalen is in Phase 2 development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 2 study in Alzheimer disease has been completed, and no active trials of Mevidalen are currently listed.
Mevidalen has been studied in one clinical trial, NCT06538116, titled A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease. That Phase 2 trial was completed and enrolled 304 participants across the United States and Japan. It was randomized, double blind, and placebo controlled, with participants aged 50 years and older.
Yes. Mevidalen is also known as LY3154207, the code name used by Eli Lilly and Company in its development records. Both names refer to the same investigational small molecule targeting DRD1 as a positive allosteric modulator for Alzheimer disease.